In recent years, acetylcholine esterase (AChE) inhibitors mostly approved by drug administration to treat AD, which rises the acetylcholine (ACh) availability to some extent alleviating this neurotransmitter insufficiency in AD patients, or they are non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, which blocks the NMDA-associated ion channel consequently lower calcium influx and restrain excitotoxicity (Kabir et al., 2019b; Kabir et al., 2019a; Kabir et al., 2020b). Here, ACHE is linked to Alzheimer disease.